Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Microbot Medical Inc (NQ: MBOT )

0.8825 +0.0025 (+0.28%)
Streaming Delayed Price Updated: 2:27 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Microbot Medical Inc

< Previous 1 2 3 Next >
Microbot Medical Shares Status Following Recent Geopolitical Events
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
The engagement is an additional step in the Company's path towards marketing clearance with the FDA 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
The presentation follows successful extensive uses of the Company’s endovascular robotic system in pre-clinical studies 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and... 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe
Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board
Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US
The study was conducted over two days by a team of global key opinion leaders and with participation of executives from the medical industry 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Expand IP protection in Japan
Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe
Company Believes the Continuous Accumulation of Peer-Reviewed Data will Accelerate the Adoption of its Novel Interventional Endovascular System Once Commercialized 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process
The data collected from the usage and experience of the medical professionals in the formative study will be used to support the Company's anticipated milestones 
From Microbot Medical Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.